The vasoactive peptide urotensin-II (U-II) has been associated with vascular remodeling in different cardiovascular disorders. Although U-II can induce reactive oxygen species (ROS) by the NADPH oxidase NOX4 and stimulate smooth muscle cell (SMC) proliferation, the precise mechanisms linking U-II to vascular remodeling processes remain unclear. Forkhead Box O (FoxO) transcription factors have b...

Preeclampsia is a hypertensive disorder of pregnancy caused by abnormal placental function, partly because of chronic hypoxia at the utero-placental junction. The increase in levels of soluble vascular endothelial growth factor receptor 1, an antiangiogenic agent known to inhibit placental vascularization, is an important cellular factor implicated in the onset of preeclampsia. We investigated ...

Abstract: Let G=(V,E) be a graph and let f:V(G)→{0,1,2} be a function‎. ‎A vertex v is protected with respect to f‎, ‎if f(v)>0 or f(v)=0 and v is adjacent to a vertex of positive weight‎. ‎The function f is a co-Roman dominating function‎, ‎abbreviated CRDF if‎: ‎(i) every vertex in V is protected‎, ‎and (ii) each u∈V with positive weight has a neighbor v∈V with f(v)=0 such that the func...

OBJECTIVE This aim of the study is to investigate whether there are possible plasma urotensin-II (U-II) and neurokinin B (NKB) level changes in patients with acute myocardial infarction (AMI) or not and plasma urotensin-II (U-II) and neurokinin B (NKB) level changes in patients with acute myocardial infarction (AMI) and stable coronary artery disease (CAD) and to evaluate whether there is any r...

This communication influences on magnetohydrodynamic flow of viscoelastic fluid with magnetic field induced by oscillating plate. General solutions have been found out for velocity and shear stress profiles using mathematical transformations (Integral transforms). The governing partial differential equations have been solved analytically under boundary conditions u(0,t)=A_0 H(t)sinΩt and u(0,t)...

This study investigated how lycopene affected urotensin-II- (U-II-) induced cardiomyocyte hypertrophy and the possible implicated mechanisms. Neonatal rat cardiomyocytes were exposed to U-II (1 nM) either exclusively or following 6 h of lycopene pretreatment (1-10  μ M). The lycopene (3-10  μ M) pretreatment significantly inhibited the U-II-induced cardiomyocyte hypertrophy, decreased the produ...

Human urotensin-II (hU-II) is one of the most potent vasoconstrictors in mammals. Although both hU-II and its receptor, GPR14, are detected in several tissues, kidney is a major source of U-II in humans. Recent studies suggest that U-II may have a possible autocrine/paracrine functions in kidney and may be an important target molecule in studying renal pathophysiology. It has several effects on...

      Hyaluronidase has a panoramic use in biotechnology processes and therapy due to its therapeutic, pathophysiological, physiological and biological importance. Since much of the preparations of hyaluronidases are from animal source (bovine and ovine testicular sources) with limited sources of microbial origin, that prompted the authors to screen and isolate a new promising bacterial strain ...

Abiotic reduction of 0.1 mM U(VI) by Fe(II) in the presence of synthetic iron oxides (biogenic magnetite, goethite, and hematite) and natural Fe(III) oxide-containing solids was investigated in pH 6.8 artificial groundwater containing 10 mM NaHCO3. In most experiments, more than 95% of added U(VI) was sorbed to solids. U(VI) was rapidly and extensively (> or = 80%) reduced in the presence of sy...